The COVID Treatment that Missed its Target

Researchers explain why those at highest risk for severe COVID-19 often least likely to get monoclonal antibodies. People over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs) — a highly effective

More
4 mins read

Is Omicron really ‘milder’? Not exactly.

The SARS-CoV-2 Omicron variant’s “milder” outcomes are likely due to more population immunity rather than the virus’ properties, according to a paper by William Hanage, associate professor of epidemiology at Harvard T.H. Chan School of Public Health, and Roby Bhattacharyya, assistant professor

More
2 mins read

Willing but unable to get COVID shot

British Reporter — Study of racial, ethnic disparities in vaccine rates suggests mistrust of system plays role but unequal access may be greater culprit in U.S. People of color in the U.S. and U.K. were up to three times likelier than white people

More
5 mins read
1 2 3 4 8